Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 10/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5884095 | 0.94 | MMP2 (0.48) | ADAM17MMP13ADAMTS4MMP2MMP12 | |
| SCHEMBL5883940 | 0.86 | ADAM17 (0.66) | ADAM17MMP13ADAMTS4MMP2 | |
| SCHEMBL5885016 | 0.82 | ADAM17 (0.54) | ADAM17MMP2MMP12 | |
| SCHEMBL5884340 | 0.81 | ADAM17 (0.59) | ADAM17MMP2 | |
| SCHEMBL15668853 | 0.80 | LMNA (0.57) | — | |
| SCHEMBL6263430 | 0.79 | MMP13 (0.57) | ADAM17MMP13ADAMTS4MMP2 | |
| SCHEMBL5884634 | 0.78 | MMP13 (0.57) | ADAM17MMP13ADAMTS4MMP2 | |
| SCHEMBL1504715 | 0.77 | ADAM17 (0.64) | ADAM17MMP13MMP2MMP12 | |
| SCHEMBL5883829 | 0.76 | ADAM17 (0.63) | ADAM17MMP13ADAMTS4MMP2 | |
| SCHEMBL5887895 | 0.76 | ADAM17 (0.61) | ADAM17MMP13ADAMTS4MMP2MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP9, ADAM17, MMP3 | ADAM17 2/4885MMP13 8/4885ADAMTS4 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.